Literature DB >> 12006898

Interactive model of therapeutic response in panic disorder: moclobemide, a case in point.

E H Uhlenhuth1, Teddy D Warner, William Matuzas.   

Abstract

It was proposed that pre-post regression slopes be used to index treatment response when the effect of baseline scores differed among treatments (interaction between treatment and baseline score). Reanalyses of two studies using imipramine and fluoxetine in panic disorder showed doserelated decreases in pre-post slopes for the frequency of unexpected panic attacks, but not for the frequency of situational panic attacks or measures of agoraphobia. This report presents similar analyses of data from a study using moclobemide. Patients (N = 452) with panic disorder were randomized to placebo or a fixed dose of moclobemide (75, 150, 300, 600, or 900 mg/day). They were treated double-blindly and evaluated at baseline and 1, 2, 3, 4, 6, and 8 weeks later. The authors analyzed the frequency of unexpected and situational panic attacks compiled from a daily diary, and fear and avoidance ratings based on the patient's main phobia using baseline (pre) and end-point (post) values for all randomized patients. Adjoining dose groups were combined. Both unexpected and situational panic attacks showed systematic doserelated suppression of pre-post treatment slopes. Neither pre-post slopes nor adjusted posttreatment means for fear and avoidance differed reliably between treatment arms. This study replicates the authors' earlier findings, except for situational panic attacks, which probably were not reliably identified. Antidepressants selectively suppress panic attacks, especially unexpected attacks, but not agoraphobia. The findings are consistent with the hypothesis that panic disorder with agoraphobia has clinically separable biologic and cognitive components that respond differentially to treatment. Antidepressants benefit primarily patients with many unexpected panic attacks. Investigators should evaluate pre-post treatment slopes before comparing adjusted posttreatment means (analysis of covariance).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12006898     DOI: 10.1097/00004714-200206000-00008

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  6 in total

1.  Improved statistical analysis of moclobemide dose effects on panic disorder treatment.

Authors:  Donald C Ross; Donald F Klein; E H Uhlenhuth
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-11-21       Impact factor: 5.270

Review 2.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

Review 3.  Diagnosis and treatment of agoraphobia with panic disorder.

Authors:  Giulio Perugi; Franco Frare; Cristina Toni
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

4.  Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively.

Authors:  Samuel R Chamberlain; David S Baldwin
Journal:  CNS Drugs       Date:  2021-07-09       Impact factor: 5.749

5.  Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition.

Authors:  Giampaolo Perna; Silvia Daccò; Roberta Menotti; Daniela Caldirola
Journal:  Neuropsychiatr Dis Treat       Date:  2011-10-19       Impact factor: 2.570

Review 6.  Antidepressants versus placebo for panic disorder in adults.

Authors:  Irene Bighelli; Mariasole Castellazzi; Andrea Cipriani; Francesca Girlanda; Giuseppe Guaiana; Markus Koesters; Giulia Turrini; Toshi A Furukawa; Corrado Barbui
Journal:  Cochrane Database Syst Rev       Date:  2018-04-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.